Advertisement
U.S. markets close in 3 hours 52 minutes
  • S&P 500

    5,252.08
    +3.59 (+0.07%)
     
  • Dow 30

    39,783.78
    +23.70 (+0.06%)
     
  • Nasdaq

    16,384.40
    -15.12 (-0.09%)
     
  • Russell 2000

    2,134.89
    +20.54 (+0.97%)
     
  • Crude Oil

    82.63
    +1.28 (+1.57%)
     
  • Gold

    2,236.10
    +23.40 (+1.06%)
     
  • Silver

    24.91
    +0.15 (+0.62%)
     
  • EUR/USD

    1.0797
    -0.0033 (-0.30%)
     
  • 10-Yr Bond

    4.1850
    -0.0110 (-0.26%)
     
  • dólar/libra

    1.2628
    -0.0010 (-0.08%)
     
  • USD/JPY

    151.3540
    +0.1080 (+0.07%)
     
  • Bitcoin USD

    70,971.57
    +1,701.23 (+2.46%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,966.50
    +34.52 (+0.44%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

FDA: Data suggests AstraZeneca drug may increase death rate

(Changes to say Friday in first paragraph)

April 10 (Reuters) - AstraZeneca Plc's diabetes drug Onglyza appears to be associated with an increased rate of death, according to a review of data published by the U.S. Food and Drug Administration on Friday.

While the primary clinical trial results did not show a statistically significant increase in the rate of death, a more detailed analysis examining only patients who took Onglyza suggests "a significantly increased risk of all-cause mortality," FDA staff said in their review.

The FDA said the causes of death were often "multifactorial" and some patients may have had several serious medical conditions in the days and weeks prior to death. Still, the FDA said it "is not reassured that the observation that causes of death span multiple disparate etiologies, and we do not necessarily view this pattern of variable causes as evidence the mortality signal is due to chance."

(Reporting by Toni Clarke in Washington)

Advertisement